Amneal 制药

最新新闻

• 评级变动
  Goldman Sachs Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $19
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $22
  \u5e02\u573a\u8d44\u8baf · 2026/8/26
• 评级变动
  Piper Sandler Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2026/5/26
• J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• 评级变动
  Goldman Sachs Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/4/23
• 评级变动
  Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $16
  \u5e02\u573a\u8d44\u8baf · 2026/5/20
• 评级变动
  UBS Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• 评级变动
  Goldman Sachs Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $19
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• 评级变动
  Piper Sandler Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/6/4
• 评级变动
  Goldman Sachs Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/4/23
• 评级变动
  UBS Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• 评级变动
  Goldman Sachs Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/5/28
• 评级变动
  Goldman Sachs Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $21
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• 评级变动
  Leerink Partners Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  UBS Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $25
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• Leerink Partners Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/9/17

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。